Rodent models of streptozotocin‐induced diabetic nephropathy (Methods in Renal Research)

SUMMARY:  Streptozotocin‐induced pancreatic injury is commonly used for creating rodent models of type 1 diabetes which develop renal injury with similarities to human diabetic nephropathy. This model can be established in genetically modified rodents for investigating the role of molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. In this report, the authors describe and compare the current protocols being used to establish models of diabetic nephropathy in rat and mouse strains using streptozotocin. The authors also list some of the histological criteria and biochemical measurements which are being used to validate these models. In addition, our review explains some of the key aspects involved in these models, including the impact of streptozotocin‐dosage, uninephrectomy, hypertension and genetically modified strains, which can each affect the development of disease and the interpretation of findings.

[1]  R. Atkins,et al.  Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Cooper,et al.  Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. , 2004, Kidney international.

[3]  G. Jerums,et al.  Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat , 1989, Diabetologia.

[4]  G. Jerums,et al.  Glomerular Filtration Rate in Streptozocin-Induced Diabetic Rats: Role of Exchangeable Sodium, Vasoactive Hormones, and Insulin Therapy , 1990, Diabetes.

[5]  M. Cooper,et al.  A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.

[6]  M. Cooper,et al.  Role of Angiotensin II and Bradykinin in Experimental Diabetic Nephropathy: Functional and Structural Studies , 1997, Diabetes.

[7]  M. Cooper,et al.  Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  G. Jerums,et al.  Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. , 1988, American journal of hypertension.

[9]  Jianping Jin,et al.  Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. , 2005, Diabetes.

[10]  Merlin C. Thomas,et al.  PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Min Zhao,et al.  Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. , 2004, American journal of physiology. Renal physiology.

[12]  K. Thai,et al.  Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression. , 2000, Kidney international.

[13]  T. Meyer,et al.  Impact of genetic background on nephropathy in diabetic mice. , 2006, American journal of physiology. Renal physiology.

[14]  N. Gretz,et al.  Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. , 2007, Kidney international.

[15]  Merlin C. Thomas,et al.  PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse , 2006 .

[16]  W. W. Nichols,et al.  Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. , 1995, Toxicology and applied pharmacology.

[17]  R. Atkins,et al.  Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. , 2006, Kidney international.

[18]  Merlin C. Thomas,et al.  Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.

[19]  W. Alborn,et al.  The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity. , 2006, Biochemical pharmacology.

[20]  R. Zatz,et al.  Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. , 2003, Kidney international.

[21]  M. Cooper,et al.  Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.

[22]  C. Johnston,et al.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy , 2003, Diabetologia.

[23]  G. Rangan,et al.  Can murine diabetic nephropathy be separated from superimposed acute renal failure? , 2005, Kidney international.

[24]  B. Klanke,et al.  Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. , 2007, American journal of physiology. Renal physiology.